IGC
IGC Pharma, Inc.0.3360
+0.0020+0.6%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
31.20MP/E (TTM)
-Basic EPS (TTM)
-0.07Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
8-K
Annual meeting approvals passed
IGC Pharma's stockholders approved key measures at the October 10, 2025, annual meeting, electing Ram Mukunda and James Moran as Class C directors through 2028 while ratifying Manohar Chowdhry & Associates as auditors for 2026. They greenlit 5 million common shares for employee incentives and boosted authorized shares from 150 million to 600 million. This expands equity tools for talent retention. Yet dilution risks loom for existing holders.
8-K
IGC sells hemp assets for $2.7M
IGC Pharma's subsidiary Holi Hemp LLC signed a $2.7 million asset sale agreement on September 29, 2025, transferring equipment, inventory, and a ready-to-move facility in Vancouver, Washington, to Wellness Essentials Northwest Inc., which assumes employee, lease, and operating responsibilities. The deal secures IGC preferential supply rights with escalating margins from 2028 to 2030 and a 10% tag-along on any buyer resale within five years. This streamlines operations while locking in future manufacturing access. Risks include potential reversion if supply fails post-2027.
ABVC
ABVC Biopharma, Inc.
2.06-0.01
ACOG
Alpha Cognition Inc.
5.43+0.42
ADIL
Adial Pharmaceuticals, Inc
0.26-0.01
ALEC
Alector, Inc.
1.39-0.03
ALZN
Alzamend Neuro, Inc.
2.16+0.05
CGTX
Cognition Therapeutics, Inc.
1.52-0.08
GANX
Gain Therapeutics, Inc.
3.86-0.09
IMMX
Immix Biopharma, Inc.
5.94-0.27
LBRX
LB Pharmaceuticals Inc
19.82-0.04
TELO
Telomir Pharmaceuticals, Inc.
1.40-0.02